Cargando…

Low-dose versus standard-dose alteplase for intravenous thrombolysis in patients with acute ischemic stroke in Iran: Results from the safe implementation of treatments in stroke registry

Background: Rates of intracranial hemorrhage (ICH) after intravenous thrombolysis (IVT) differ depending on ethnicity, one reason that few Eastern countries have approved a lower dose of alteplase. Data in this regard are scarce in the Middle Eastern region. Methods: The present retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sadeghi-Hokmabadi, Elyar, Ghoreishi, Abdoreza, Rikhtegar, Reza, Sariaslani, Payam, Rafie, Shahram, Vakilian, Alireza, Sharifipour, Ehsan, Mehrpour, Masoud, Saadatnia, Mohammad, Mirza-Aghazadeh-Attari, Mohammad, Farhoudi, Mehdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107572/ https://www.ncbi.nlm.nih.gov/pubmed/38011433 http://dx.doi.org/10.18502/cjn.v20i4.8346

Ejemplares similares

Outcome predictors in anterior and posterior ischemic strokes: a study based on the Iranian SITS registry
por: Jalali, Nazanin, et al.
Publicado: (2023)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Efficacy and safety of decompressive craniectomy in acute ischemic stroke patients treated with intravenous thrombolysis
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2023)

Early and intermediate prognosis of intravenous thrombolytic therapy in acute ischemic stroke subtypes according to the causative classification of stroke system
por: Pashapour, Ali, et al.
Publicado: (2013)

Effect of IMOD(™) on the inflammatory process after acute ischemic stroke: a randomized clinical trial
por: Farhoudi, Mehdi, et al.
Publicado: (2013)

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
por: Zhu, Annie, et al.
Publicado: (2022)

Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis
por: Tan, Ge, et al.
Publicado: (2017)

Evaluation of the neuroprotective effect of dextromethorphan in the acute phase of ischaemic stroke
por: Mousavi, Seyed Ali, et al.
Publicado: (2011)

Public knowledge of people visiting Imam Reza hospital regarding stroke symptoms and risk factors
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2019)

Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2018)

Silver Jubilee of Stroke Thrombolysis With Alteplase: Evolution of the Therapeutic Window
por: Pan, Yuanmei, et al.
Publicado: (2021)

Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
por: Yang, Nan, et al.
Publicado: (2023)

Renal Dysfunction Is an Independent Risk Factor for Poor Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis: A New Cutoff Value
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2017)

Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials
por: Xu, Na, et al.
Publicado: (2018)

Eligibility Assessment for Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients; Evaluating Barriers for Implementation
por: Ayromlou, Hormoz, et al.
Publicado: (2014)

Electrical interferential current stimulation versus electrical acupuncture in management of hemiplegic shoulder pain and disability following ischemic stroke-a randomized clinical trial
por: Eslamian, Fariba, et al.
Publicado: (2020)

Effect of Alteplase Thrombolysis on Coagulation Function and Nerve Function of Patients with Ischemic Stroke
por: Zhao, Hong-Ying, et al.
Publicado: (2022)

A Comparative Study of Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase Versus Tenecteplase
por: Ezzeldin, Mohamad, et al.
Publicado: (2023)

Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial
por: Zhou, Zien, et al.
Publicado: (2021)

Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke
por: Zhai, Mingfeng, et al.
Publicado: (2023)

Alteplase for acute ischemic stroke: 2 years in a community hospital without previous experience in stroke thrombolysis
por: Estella, A, et al.
Publicado: (2008)

Statistical analysis plan for evaluating low‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)
por: Anderson, Craig S., et al.
Publicado: (2015)

Ischemic stroke as the initial manifestation of atrial fibrillation; is it higher than expected?
por: Sadeghi Hokmabadi, Elyar, et al.
Publicado: (2021)

Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset
por: Wang, Zekun, et al.
Publicado: (2023)

Intravenous Thrombolysis for Acute Ischemic Stroke Due to Cardiac Myxoma
por: Esmaeili, Sara, et al.
Publicado: (2020)

Simple In-Hospital Interventions to Reduce Door-to-CT Time in Acute Stroke
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Bolus-Infusion Delays of Alteplase during Thrombolysis in Acute Ischaemic Stroke and Functional Outcome at 3 Months
por: Acheampong, Paul, et al.
Publicado: (2014)

Predictors of Postthrombolysis Outcome and Symptomatic Postthrombolysis Hemorrhage following Intravenous Thrombolysis with Alteplase for Acute Ischemic Stroke
por: Das, Suman, et al.
Publicado: (2020)

Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study
por: Dhar, Nikita, et al.
Publicado: (2022)

The predictive value of red cell distribution width for stroke severity and outcome
por: Shahsavarinia, Kavous, et al.
Publicado: (2020)

Stroke subtypes, risk factors and mortality rate in northwest of Iran
por: Farhoudi, Mehdi, et al.
Publicado: (2017)

Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3–4.5 h
por: Chen, Chih-Hao, et al.
Publicado: (2022)

Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis
por: Xu, Jiawen, et al.
Publicado: (2023)

Low versus standard dose intravenous alteplase in the treatment of acute ischemic stroke in Egyptian patients
por: Salem, Gelan M., et al.
Publicado: (2021)

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
por: Zhai, Mingfeng, et al.
Publicado: (2023)

THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial
por: Koga, Masatoshi, et al.
Publicado: (2014)

Spontaneous Splenic Rupture Following Intravenous Thrombolysis with Alteplase Applied as Stroke Therapy – Case Report and Review of Literature
por: Aleksic-Shihabi, Anka, et al.
Publicado: (2016)

Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial
por: Koga, Masatoshi, et al.
Publicado: (2020)

Intravenous Thrombolysis With Alteplase at 0.6 mg/kg in Patients With Ischemic Stroke Taking Direct Oral Anticoagulants
por: Okada, Takashi, et al.
Publicado: (2022)

Effect of admission serum glucose on the clinical prognosis of patients with acute ischemic stroke receiving alteplase intravenous thrombolysis
por: Huang, Pan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_abjo9vjao04cetei4cr0ubjo3c